Indoco Remedies Q4 Review- Higher Remediation Expenses, Promotional Cost Impacted Margins: Prabhudas Lilladher
Management guided for improved margins in FY25.17-05-2024
17-05-2024
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, the audio recording of the earnings conference call in respect of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2024 held today i.e. 16th May, 2024 at 03:30 p.m. (IST) is available on the Company's website at https://www.indoco.com/inv-fin-concall-transcripts.asp. The Earnings Conference Call concluded at 04.20 p.m. (IST) on 16th May, 2024.16-05-2024
Indoco Remedies Results Earnings Call for Q4FY24
Conference Call with Indoco Remedies Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.16-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Indoco Remedies Ltd.
Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year. EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year. Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year. FY24 Financial Highlights: For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year. EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year. Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.” Result PDF16-05-2024
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
USFDA successfully completes inspection at Indoco''s API Kilo Lab manufacturing facility and IAS division without any observations16-05-2024
INDOCO REMEDIES LTD. - 532612 - Financial Results For The Quarter And Year Ended 31St March, 2024
Approval of Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 202416-05-2024
INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 16Th May, 2024
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 16th May, 2024 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2024 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 77th Annual General Meeting, recommended a Dividend of Rs. 1.50 per equity share on face value of Rs. 2/- for the financial year 2023-2024.16-05-2024
INDOCO REMEDIES LTD. - 532612 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (LODR)Regulations,2015, we are enclosing herewith in Annexure A the details of the Show Cause Notice received from the Goods and Service Tax (GST) Authority.10-05-2024
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call on Audited Financial Results for fourth quarter and year ended 31st March, 202408-05-2024
INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Audited Results & Final Dividend.
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2024. 2. To recommend a final dividend, if any for the financial year ending 31st March, 2024.08-05-2024